Key result
RNA-based therapeutics such as pelacarsen and olpasiran can reduce lipoprotein(a) levels by up to 90%, supporting the routine measurement of Lp(a) to identify high-risk patients.
Why the study?
Current LDL-C-lowering therapies minimally lower Lp(a), highlighting the need to review the clinical importance and therapeutic consequences of Lp(a) measurement.
Routine measurement of Lp(a) is recommended at least once to identify high-risk patients who may benefit from aggressive risk factor modification and future Lp(a)-lowering therapies.
No takes yet. Share an insight, caveat, or question.
Lp(a) screening may identify candidates for emerging therapies; leaves open whether Lp(a) reduction improves cardiovascular outcomes.
Nurmohamed et al. (2022) conducted a review in Atherosclerotic cardiovascular disease (ASCVD) and aortic valve disease. Lipoprotein(a) measurement and lowering therapies was evaluated. RNA-based therapeutics such as pelacarsen and olpasiran can reduce lipoprotein(a) levels by up to 90%, supporting the routine measurement of Lp(a) to identify high-risk patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: